Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

TransMID phase III program agreed under SPA

May 13, 2004

SPA for phase III GVAX prostate cancer vaccine trial

May 12, 2004

Novel human anticancer vaccine elicits cellular responses

May 12, 2004

Australian Pentrys phase II trial commences

May 5, 2004

Phase II TroVax trial cleared to commence for metastatic renal cancer

May 3, 2004

Positive data for HuMax-CD4 in phase II CTCL studies

April 30, 2004

Esteve takes marketing rights to Wilex's Rencarex in Southern Europe

April 30, 2004

Phase III results of R-1549 in ovarian cancer disappoint

April 28, 2004

Aastrom receives grant to develop immunotherapy for malignant melanoma

April 27, 2004

Phase II trial studies Xcellerated T Cells for multiple myeloma

April 20, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...